SOURCE: RxElite, Inc.

August 06, 2008 08:30 ET

RxElite Inc. Announces Newly Updated FineTech Pharmaceutical Ltd. API Website

MERIDIAN, ID--(Marketwire - August 6, 2008) - RxElite, Inc. (OTCBB: RXEI) announced today the launch of a redesigned and updated website for their recently acquired and wholly owned subsidiary, FineTech Pharmaceutical Ltd. The new customer-focused website at will provide up-to-date information on both products and services offered by FineTech.

The new design focuses on providing competitive business solutions to our customers. The website presents an improved look and feel with a fresh contemporary design. Improvements have been made to the architecture to provide a natural flow and more in-depth information with several new pages.

According to Rick Schindewolf, RxElite's Senior Vice President of Business Development, "This new website is yet another step in developing and growing our FineTech API business. This website provides potential customers valuable information on our development capabilities and API products and gives them a fast and easy way to contact us for additional information."

The website is organized into four sections: Company Overview, Products, Services, and Facilities. Browse through the Services section at to discover the capabilities and expertise of FineTech.

About RxElite, Inc.

RxElite, Inc. develops, manufactures, and markets generic prescription drug products in specialty generic markets. These markets include products in the areas of anesthesia, sterile liquid dose drugs (including respiratory inhalation drugs, ophthalmics, and injectable drugs), complex active pharmaceutical ingredients, and other specialty areas.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 involving known and unknown risks, delays, and uncertainties that may cause our actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks, delays, and uncertainties include, but are not limited to: risks associated with the uncertainty of future financial results, our reliance on our sole supplier, the limited diversification of our product offerings, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.

Contact Information

  • For more information:

    Corporate Information
    Ph: (208) 288-5550
    Toll Free: (800) 414-1901
    Fax: (208) 288-1191

    Investor Relations
    Ric Tener
    PH: (208) 288-5550
    Fax: (208) 288-1191
    Email: Email Contact